Bleomycin pulmonary toxicity in adult Saudi patients with Hodgkin's lymphoma.

Abstract

BACKGROUND:

Bleomycin pulmonary toxicity (BPT) has been described in Hodgkin's lymphoma (HL) patients treated with bleomycin-containing chemotherapy regimens.

METHODOLOGY:

We reviewed the records of 164 consecutive HL patients.

RESULTS:

BPT was observed in 24 of 164 patients (15%). Older age and history of concomitant lung disease were significantly associated with approximately threefold (odds ratio: 3.38; 95% CI: 1.25-9.13; p = 0.02) and sevenfold (odds ratio: 7.19; 95% CI: 2.64-19.54; p < 0.0001) increase in BPT risk, respectively. The actuarial 5-year progression-free and overall survival for BPT and non-BPT groups, were not significantly different.

CONCLUSION:

In Saudi Arabian HL patients, the risk of BPT and its effect on survival outcome were comparable to that reported from developed countries.

• Authors: Wafa'a A Al-Jizani, Mubarak M Al-Mansour, Turki M Al-Fayea, Ruaa U Shafi, Ghieth A Kazkaz, Ali M Bayer, Meteb E Al-Foheidi, Ezzeldin M Ibrahim
• Journal: Future oncology (London, England) (Future Oncol) Vol. 11 Issue 15 Pg. 2149-57 ( 2015) ISSN: 1744-8301 [Electronic] England
• PMID: 26235180 (Publication Type: Journal Article)

Chemical References

• Bleomycin

Topics

• Adult
• Aged
• Bleomycin (administration & dosage, adverse effects)
• Disease-Free Survival
• Female
• Hodgkin Disease (complications, drug therapy, pathology)
• Humans
• Lung (drug effects, physiopathology)
• Lung Diseases (chemically induced, physiopathology)
• Male
• Middle Aged
• Saudi Arabia
• Treatment Outcome